ABSTRACT OF DISCLOSURE

A method and composition for the treatment of respiratory disease, particularly bronchial asthma, is provided. The method and composition is provided in the form of an oral medication and includes a combination of known medications so as to avoid unnecessary undesirable reactions. The treatment composition and regimen includes a pair of compatible receptor antagonists and an adrenergic bronchodilator. The pair of compatible receptor antagonists include a leukotriene receptor antagonist and a histamine H_1-receptor antagonist. The adrenergic bronchodilator is a beta$_2$-adrenergic bronchodilator.

5

10